Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Lilly is considering whether any of its diabetes drugs could be repositioned for additional uses to treat Alzheimer's disease and has begun some preliminary investigations of the area.
The company told PMLiVE that, although the work is a long way behind its focus on the 'amyloid hypothesis' and role of the Tau protein, the potential of diabetes drugs is ?an area we are monitoring and interested in?.
?We're certainly doing some preclinical investigation of the potential of that kind of approach,? Lilly's chief scientific officer for neuroscience Dr Mike Hutton told PMLiVE.
http://www.pmlive.com/pharma_news/lilly_exploring_diabetes_portfolio_for_alzheimers_potential_520241
The company told PMLiVE that, although the work is a long way behind its focus on the 'amyloid hypothesis' and role of the Tau protein, the potential of diabetes drugs is ?an area we are monitoring and interested in?.
?We're certainly doing some preclinical investigation of the potential of that kind of approach,? Lilly's chief scientific officer for neuroscience Dr Mike Hutton told PMLiVE.
http://www.pmlive.com/pharma_news/lilly_exploring_diabetes_portfolio_for_alzheimers_potential_520241